Breakfast with Amazon and dinner with Google: leadership tips from the man driving Ferring's relentless rise in the USA
The growth of privately-held Swiss drugmaker Ferring Pharmaceuticals in the US market has been nothing short of remarkable.
Over the last decade, double-digit US sales rises in many years has led to the total revenue from this market more than doubling, making it the largest contributor of any region to Ferring’s earnings, which reached $2.4 billion globally in 2017.
The Pharma Letter asked Paul Navarre, chief executive of its US operations, why he thought the company had achieved a rate of growth that outpaced so many others in the industry in this period. His answers reflect not just the ambition and ability to deliver of Ferring over a long period, but also an approach to leadership that strives to make a major difference in healthcare.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze